SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-065914
Filing Date
2021-05-13
Accepted
2021-05-13 16:02:19
Documents
14
Period of Report
2021-05-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tm2110957d1_8k.htm   iXBRL 8-K 27091
2 EXHIBIT 99.1 tm2110957d1_ex99-1.htm EX-99.1 76238
6 GRAPHIC image_001.jpg GRAPHIC 4325
  Complete submission text file 0001104659-21-065914.txt   294028

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA casi-20210513.xsd EX-101.SCH 3187
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE casi-20210513_lab.xml EX-101.LAB 34592
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE casi-20210513_pre.xml EX-101.PRE 22711
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2110957d1_8k_htm.xml XML 3590
Mailing Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850
Business Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850 240-864-2600
CASI Pharmaceuticals, Inc. (Filer) CIK: 0000895051 (see all company filings)

IRS No.: 581959440 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-20713 | Film No.: 21919491
SIC: 2836 Biological Products, (No Diagnostic Substances)